Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

Kinslow, Connor J.; May, Michael; Saqi, Anjali; Shu, Catherine A.; Chaudhary, Kunal; Wang, Tony J. C.; Cheng, Simon K.

doi:10.1016/j.cllc.2019.07.011

Cited by 49 publications

(61 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have proposed new classifications of pLCNEC based on clinical, pathological and genotyping characteristics, which can be used to classify LCNEC into SCLC-like and NSCLC-like LCNEC [38][39][40][41]. This would be important for the prognostic evaluation and selection of adjuvant therapies for patients.…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Chen

Zhang

Huang

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. Thus, the clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored. Results The clinical data of 59 patients (48 males and 11 females) who were treated by surgery and diagnosed with pLCNEC by postoperative pathology at Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively. The median patient age was 62 years (38–79 years), and the median duration of disease was 2 months (0.5–18 months). Compared with other lung malignancies, pLCNEC lacks specific clinical symptoms and imaging features, and preoperative biopsy pathology is often insufficient to confirm the diagnosis. The corresponding numbers of patients who were classified into stages I, II, III and IV according to the postoperative pathological tumour-nodal-metastasis stage were 25, 12, 15 and 7, respectively. The median overall survival was 36 months (0.9–61.1 months). The 1-year, 3-year and 5-year survival rates were 76.3%, 49% and 44.7%, respectively. The tumour stage exerted a significant effect on survival (Cox multivariate analysis p < 0.05). Conclusions For patients with resectable pLCNEC, multidisciplinary therapy based on surgery may have good survival benefits, and tumour stage is an independent risk factor for the prognosis of pLCNEC.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Chen

Zhang

Huang

et al. 2021

Orphanet J Rare Dis

View full text Add to dashboard Cite

show abstract

“…The increasing incidence has been reported recently, with a rate raised from 0.26 in 2004 to 0.39 per 100,000 people in 2015 (5)(6)(7). Most LCNEC patients are male and their median age is 66 (5)(6)(7). There is a high frequency of cigarette smoking history, up to 98% (4,6).…”

Section: Introductionmentioning

confidence: 94%

“…Large cell neuroendocrine carcinoma (LCNEC) is rare, accounting for 1-3% of all lung cancer cases (4,5). The increasing incidence has been reported recently, with a rate raised from 0.26 in 2004 to 0.39 per 100,000 people in 2015 (5)(6)(7). Most LCNEC patients are male and their median age is 66 (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments

et al. 2021

View full text Add to dashboard Cite

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive neoplasm with poor prognosis. Histologic diagnosis of LCNEC is not always straightforward. In particular, it is challenging to distinguish small cell lung carcinoma (SCLC) or poorly differentiated carcinoma from LCNEC. However, histological classification for LCNEC as well as their therapeutic management has not changed much for decades. Recently, genomic and transcriptomic analyses have revealed different molecular subtypes raising hopes for more personalized treatment. Two main molecular subtypes of LCNEC have been identified by studies using next generation sequencing, namely type I with TP53 and STK11/KEAP1 alterations, alternatively called as non-SCLC type, and type II with TP53 and RB1 alterations, alternatively called as SCLC type. However, there is still no easy way to classify LCNEC subtypes at the actual clinical level. In this review, we have discussed histological diagnosis along with the genomic studies and molecular-based treatment for LCNEC.

show abstract

“…Traditional survival analysis methods such as Kaplan-Meier method and Cox model may had limitations because they ignored the competing risk factors between outcome events [10]. In the previous survival analysis of LCNEC, competing risk events were treated as censored, which may lead to the risk of bias [11].Moreover, a large-sample study of rare diseases can be conducted by utilizing a population-based cancer database, and the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute covers approximately 34.6% of the U.S. population [12][13][14]. Analysis of the SEER database should provide useful information about prognostic factors in patients with pulmonary LCNEC after surgery.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors of patients with pulmonary large-cell neuroendocrine carcinoma after surgery: a competing risk analysis

Huang¹,

Liu²,

Cai³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare primary malignant tumor with a poor prognosis. Our aim was to determine the prognostic factors of patients with pulmonary LCNEC after surgery based on competing risk model. Methods: Patients were identified in the Surveillance, Epidemiology, and End Results (SEER) database. For single outcome events, Kaplan-Meier method and Cox proportional risk model were used for analysis. Competing risk model was used in the analysis of multiple outcome events to adjust potential confounding factors. Competing risk model was used to calculate the cumulative incidence function of LCNEC-specific death. The Fine-Gray model was used for multivariate analysis to determine independent prognostic factors.Results: We finally screened 614 patients with pulmonary LCNEC who underwent surgery. The univariate analysis showed that T stage, N stage, M stage, regional nodes positive (RNP), and radiotherapy were significantly associated with the cumulative incidence of LCSD (P < 0.05). The Fine-Gray model showed that age, T stage, M stage, RNP, radiotherapy, and chemotherapy were independent prognostic factors for patients with pulmonary LCNEC after surgery (P < 0.05). Conclusion: Based on the competing risk model, we estimated a more accurate cumulative incidence of LCNEC-specific death and prognostic factors for patients with pulmonary LCNEC after surgery.

show abstract

Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

Cited by 49 publications

References 34 publications

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments

Prognostic factors of patients with pulmonary large-cell neuroendocrine carcinoma after surgery: a competing risk analysis

Contact Info

Product

Resources

About